There is exciting news from the cancer immunotherapy field: a personalized mRNA cancer vaccine for melanoma has succeeded in a large Phase 3 clinical trial when combined with immunotherapy.
The treatment, called intismeran autogene (V940), is a personalized mRNA-based cancer vaccine developed by Moderna and Merck. It uses genetic information from an individual patient’s tumor to teach the immune system to recognize and attack that cancer.
For the Gorlin syndrome community, this is worth watching with cautious enthusiasm. This is not a vaccine for basal cell carcinoma (BCC), and there is currently no evidence that it could prevent or treat the many routine BCCs experienced by people with Gorlin syndrome.
What makes this development particularly exciting is the platform itself. Its success in melanoma is another encouraging sign that researchers are making progress on the long-standing challenge of effectively training the immune system to recognize and fight cancer. If this approach proves successful across additional cancers, its potential applications could expand considerably.
Could that eventually include BCC? Potentially. People with Gorlin syndrome can develop a very high burden of BCCs, making new treatment approaches especially important. One possibility worth exploring is whether a similar strategy could someday be useful for advanced BCCs, particularly tumors that have become—or are likely to become—resistant to current treatments.
For the numerous smaller, more typical BCCs associated with Gorlin syndrome, how an individualized cancer vaccine could be practical or useful is much less clear.
So, this isn't a new treatment for Gorlin syndrome today. But it is an important proof of concept for a rapidly advancing technology—and one we'll be watching closely for its potential application to BCC.